Oncology

In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of dostarlimab as therapy for adult patients with recurrent or advanced solid tumors with deficient mismatch repair.

Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.

Pembrolizumab has been approved by the European Commission in 5 indications of solid tumors that are microsatellite instability–high or deficient mismatch repair.

Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.

Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.

Bevacizumab-maly was approved by the FDA across numerous cancer indications, becoming the third FDA-approved bevacizumab biosimilar.

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.

Patients with advanced solid tumors experienced an increase in dose-dependent T-cell proliferation following treatment with MEDI5752.

Patients with solid malignancies may benefit from treatment with next-generation PARP inhibitor AZD5305, according to findings from the phase 1/2a PETRA study.

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Based on results from the EPIK-P1 trial, the FDA has granted accelerated approval to alpelisib for PIK3CA-related overgrowth spectrum.

Patients with cancer are at a higher risk for adverse financial effects compared with those who have not been diagnosed.

Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.

Maurie Markman, MD, sits down with CancerNetwork® to discuss proposed legislation that would put a time limit on how long drugs with an accelerated approval can stay on the market, and how that may negatively impact patients with cancer.

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

In recognition of Black History Month, key opinion leaders from the community oncology space and beyond speak to how organizations are working to diversify clinical cancer research and combat outcome disparities.

Women undergoing treatment with immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials were at a significantly increased risk of severe adverse effects compared with men.

Findings from a systematic review that evaluated bevacizumab, trastuzumab, and rituximab vs respective biosimilars highlighted little difference in outcomes between treatment options.

Conflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.

The FoundationOne Tracker ctDNA monitoring assay was given breakthrough device designation by the FDA for use in early-stage cancer after curative therapy.

Cancer misinformation may be more prevalent among residents in rural vs urban areas, study finds.

A combination of sitting for longer periods a day and a lack of physical activity resulted in a higher risk of death than those who partook in physical activity.

Safety findings from the phase 1 ASPEN-01 trial support the use of evorpacept with or without pembrolizumab or trastuzumab for patients with advanced solid tumors.

A cohort study found that immune-mediated diseases were associated with a higher increased risk of total cancer, and organ-specific immune-mediated diseases were more strongly associated with local cancers than extra-local cancers.

In recognition of World Cancer Day, Daniel Vorobiof, MD, touched on the use of Belong.life, a patient-centric social and professional network, in collecting real-world data and providing patients with additional resources, and highlighted several real-world data studies that were conducted with the application’s data.

For World Cancer Day, CancerNetwork® reviews key highlights from the Cancer Facts & Figures 2022 report from the American Cancer Society, with updates in cancer incidence, mortality, and survival across patient subgroups.

Fosnetupitant demonstrated non-inferiority and a favorable safety profile vs fosaprepitant for chemotherapy-induced nausea and vomiting.

In radiation oncology and medical oncology, representation of female faculty has increased from 1970 to 2019, and representation of individuals from historically underrepresented racial and ethnic groups in medicine remains low.

Comprehensive cancer centers in Chicago and Atlanta earn national distinction as top performers in patient experience.